Drug Type Small molecule drug |
Synonyms S06593, Tripliam, Triplixam |
Target |
Action inhibitors, blockers |
Mechanism ACE inhibitors(Angiotensin-converting enzyme inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers), Symporters inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Singapore (23 May 2016), |
Regulation- |
Molecular FormulaC20H25ClN2O5 |
InChIKeyHTIQEAQVCYTUBX-UHFFFAOYSA-N |
CAS Registry88150-42-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Essential Hypertension | Singapore | 23 May 2016 |